PMID- 26207713
OWN - NLM
STAT- MEDLINE
DCOM- 20170113
LR  - 20170113
IS  - 1538-067X (Electronic)
IS  - 1092-1095 (Linking)
VI  - 19
IP  - 4
DP  - 2015 Aug
TI  - Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With 
      Invasive Breast Cancer.
PG  - 468-74
LID - 10.1188/15.CJON.468-474 [doi]
AB  - BACKGROUND: The mammalian target of rapamycin (mTOR) inhibitor everolimus is 
      approved (in combination with exemestane) for the treatment of postmenopausal 
      women with advanced hormone receptor-positive, human epidermal growth factor 
      receptor 2-negative breast cancer resistant to endocrine therapy. Stomatitis is 
      among the most frequently reported dose-limiting adverse events associated with 
      everolimus use, often requiring treatment interruption or dose reduction. 
      OBJECTIVES: This article aims to educate nurses on the identification and 
      management of stomatitis associated with mTOR inhibitors in hormone 
      receptor-positive advanced breast cancer and to assist nurses with additional 
      management techniques to improve patient outcomes. METHODS: An evaluation of the 
      literature highlighting the incidence, identification, and management of 
      stomatitis in cancer was performed with a particular focus on breast cancer. In 
      addition, the experiences of the authors' cancer center on managing stomatitis 
      are described. FINDINGS: A growing body of clinical evidence shows the benefits 
      of adding steroid-based mouth rinses to the treatment plan. Clinical experience 
      provides additional insight into stomatitis preventive and management strategies 
      for patients with breast cancer receiving treatment with everolimus.
FAU - Divers, Josephine
AU  - Divers J
AD  - Texas Oncology-Baylor Charles A. Sammons Cancer Center in Dallas.
FAU - O'Shaughnessy, Joyce
AU  - O'Shaughnessy J
AD  - Texas Oncology-Baylor Charles A. Sammons Cancer Center in Dallas.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin J Oncol Nurs
JT  - Clinical journal of oncology nursing
JID - 9705336
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/pathology
MH  - Everolimus/*adverse effects/therapeutic use
MH  - Humans
MH  - Neoplasm Invasiveness
MH  - Stomatitis/*chemically induced/prevention & control
OTO - NOTNLM
OT  - mTOR inhibitors
OT  - prevention strategies
OT  - steroid mouth rinses
OT  - stomatitis
OT  - tolerability
EDAT- 2015/07/26 06:00
MHDA- 2017/01/14 06:00
CRDT- 2015/07/25 06:00
PHST- 2015/07/25 06:00 [entrez]
PHST- 2015/07/26 06:00 [pubmed]
PHST- 2017/01/14 06:00 [medline]
AID - 10.1188/15.CJON.468-474 [doi]
PST - ppublish
SO  - Clin J Oncol Nurs. 2015 Aug;19(4):468-74. doi: 10.1188/15.CJON.468-474.